Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

13.63 -2.24 (-14.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Top movers in Friday's after hours session ↗
Via Chartmill
News headline image
2 Healthcare Stocks to Buy and 1 to Approach With Caution ↗
Recent performances don't tell the whole story. 
Via The Motley Fool
News headline image
This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy? ↗
This run could be short-lived. 
Via The Motley Fool
Topics Death
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
The growth investor kicked off this week by buying up some hard-hit stocks. 
Via The Motley Fool
Intellia Therapeutics Inc (NASDAQ:NTLA) Reports Strong Q4 2025 Revenue Beat and Confirms Key 2026 Pipeline Milestones ↗
Via Chartmill
News headline image
Why Did NTLA Stock Jump 10% In Pre-Market Today? ↗
The company announced that the U.S. FDA lifted a clinical hold on its Phase 3 trial of ATTR-CM treatment drug. 
Via Stocktwits
News headline image
Intellia (NTLA) Q4 2025 Earnings Call Transcript ↗
Intellia (NTLA) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy? ↗
Will this biotech's innovative platform finally pay off? 
Via The Motley Fool
News headline image
NTLA Stock Jumped 13% Today – What Is The Latest FDA Action All About? ↗
The U.S. Food and Drug Administration lifted the clinical hold on a Phase 3 Trial, which was imposed on October 29, 2025 following the observation of Grade 4 liver transaminases and increased total... 
Via Stocktwits
Nasdaq, S&P 500 Futures Edge Higher Ahead Of Long Weekend: Why NVDA, MU, NTLA, ASTS Are On Traders' Radar Today ↗
Via Stocktwits
Topics Stocks
News headline image
Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD ↗
ARK doubles down on a CRISPR bet as Intellia Therapeutics’ stock heads for its best week since October. 
Via Stocktwits
Topics Artificial Intelligence ETFs
News headline image
Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares ↗
Focused on CRISPR-based therapies for rare diseases and oncology, this biotech just reported a notable insider sale in public filings. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street ↗
Don't get too excited about their prospects. 
Via The Motley Fool
Topics Death
News headline image
How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint ↗
Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam. 
Via Investor's Business Daily
News headline image
Intellia (NTLA) Q3 2025 Earnings Call Transcript ↗
Intellia (NTLA) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
2 Beaten-Down Stocks to Avoid Right Now ↗
There might be plenty more downside for these biotechs. 
Via The Motley Fool
Topics Death
News headline image
This Bath & Body Works Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
This SPS Commerce Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
What 21 Analyst Ratings Have To Say About Intellia Therapeutics ↗
 
Via Benzinga
News headline image
Why Gene-Editing Giants Crispr And Intellia Just Surged ↗
The companies are working on one-and-done treatments for diseases tied to genetic problems. 
Via Investor's Business Daily
Topics Death
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies ↗
The company remains confident in its other gene-editing product, which would treat a swelling disorder. 
Via Investor's Business Daily
Topics Death
News headline image
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street ↗
Wall Street may be overestimating these companies' potential. 
Via The Motley Fool
News headline image
Discover the top movers in Friday's pre-market session. ↗
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Block Posts Downbeat Q3 Results, Joins Archer Aviation, DraftKings And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Intellia Therapeutics Inc (NASDAQ:NTLA) Plummets 24.5% After FDA Places Clinical Hold on Phase 3 Trials ↗
Intellia stock plunges after FDA places clinical hold on its Phase 3 trials for lead candidate nex-z, overshadowing Q3 earnings. 
Via Chartmill
News headline image
What's going on in today's after hours session ↗
Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as... 
Via TokenRing AI
Topics Artificial Intelligence Climate Change Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.